Back to Journals » OncoTargets and Therapy » Volume 6

Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers

Total article views   HTML views PDF downloads Totals
20,499 Dovepress* 14,635+ 3,553 18,188
PubMed Central* 5,864 1,944 7,808
Totals 20,499 5,497 25,996
*Since 5 November 2013
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
5 0 0 0 0 5

View citations on PubMed Central and Google Scholar